Compare Novavax Inc (NVAX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Workiva Inc — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Workiva Inc is far larger — about 2.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | WK | |
|---|---|---|
Market Cap | $1.30B | $3.21B |
Sector | Health | Technology |
52-Week High | $11.19 | $93.31 |
52-Week Low | $6.22 | $44.31 |
Enterprise Value | $800.50M | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Workiva (WK) trades at $57.19, up 0.02% on the day, with a bullish technical outlook from moving averages and strong analyst support. The company shows robust revenue growth, reaching $884.57M in 2025, and has consistently beaten earnings estimates in recent quarters. Recent news highlights its AI-powered platform growth and upcoming Q2 2026 results.
The stock presents a positive outlook with an 88.89% buy rating from analysts and a consensus price target of $71.00, suggesting 24% upside. Risks include high valuation multiples (P/E 238.29) and profitability challenges, with net income margin at 1.53% for 2026. Investors should weigh growth potential against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
